Clinical Trials Logo

Clinical Trial Summary

The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05444920
Study type Observational [Patient Registry]
Source IRCCS Policlinico S. Matteo
Contact Paolo Milani, MD, PhD
Phone +390382502994
Email p.milani@smatteo.pv.it
Status Recruiting
Phase
Start date July 13, 2022
Completion date November 1, 2027

See also
  Status Clinical Trial Phase
Completed NCT02595983 - The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant Phase 2
Recruiting NCT04561518 - ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Recruiting NCT05184088 - Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis Phase 3